

Drug Monograph

Drug Name: **Akynzeo® (fosnetupitant/palonosetron) injection solution**
 Drug Class: **Antiemetics, 5-HT3 and NK1 Injectable Agents**
 Prepared For: MO HealthNet
 Prepared By: Conduent

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Akynzeo is now available as a solution for injection containing 235 mg fosnetupitant/0.25 mg palonosetron in a 20 mL vial.

Manufacturer: Distributed by: Helsinn Therapeutics (U.S.), Inc., Iselin NJ 08830.

Indications: Akynzeo injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy.

Costs: \$667.80 per 20 mL vial Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List (PDL) as non-preferred

Status Recommendation: Clinical Edit PA Required
 Open Access PDL

Type of PA Criteria: Appropriate Indications Non-Preferred
 No PA Required Preferred

Prepared by: Megan Fast, PharmD.
 Date: September 30, 2020